AL-S Pharma reported positive topline results from its Phase 2 clinical trial of AP-101, a first-in-class monoclonal antibody targeting misfolded SOD1...
ANI Pharmaceuticals announced results from the NEW DAY clinical trial evaluating ILUVIEN (fluocinolone acetonide intravitreal implant) for diabetic ma...
4TEEN4 Pharmaceuticals announced the publication of data in the European Journal of Heart Failure demonstrating the efficacy and safety of procizumab,...
4B Technologies announced positive topline results from a Phase 1 study of 4B03-04, a humanized monoclonal antibody for chronic pain. The trial demon...
AB Science SA announced initial Phase 1 data for the combination of AB8939 with venetoclax for treating refractory or relapsed acute myeloid leukemia ...
AbCellera presented preclinical data on ABCL575, a half-life extended anti-OX40L monoclonal antibody for moderate-to-severe atopic dermatitis. The da...
Clinical Trial UpdatesAL-S Pharma reported positive topline results from its Phase 2 clinical trial of AP-101, a first-in-class monoclonal antibody targeting misfolded SOD1...
Clinical Trial UpdatesANI Pharmaceuticals announced results from the NEW DAY clinical trial evaluating ILUVIEN (fluocinolone acetonide intravitreal implant) for diabetic ma...
Clinical Trial Updates4TEEN4 Pharmaceuticals announced the publication of data in the European Journal of Heart Failure demonstrating the efficacy and safety of procizumab,...
Clinical Trial Updates4B Technologies announced positive topline results from a Phase 1 study of 4B03-04, a humanized monoclonal antibody for chronic pain. The trial demon...
Clinical Trial UpdatesAB Science SA announced initial Phase 1 data for the combination of AB8939 with venetoclax for treating refractory or relapsed acute myeloid leukemia ...
Clinical Trial UpdatesAbCellera presented preclinical data on ABCL575, a half-life extended anti-OX40L monoclonal antibody for moderate-to-severe atopic dermatitis. The da...
Regulatory ApprovalsInnoCare Pharma announced that its BCL2 inhibitor, Mesutoclax (ICP-248), received Breakthrough Therapy Designation from China's NMPA for treating rela...
Regulatory ApprovalsUnited Imaging announced FDA clearance for its uAngio® AVIVA interventional X-ray system. This ceiling-mounted system features intelligent robotics, ...
Regulatory ApprovalsViridian Therapeutics announced that the FDA granted Breakthrough Therapy Designation to veligrotug, its lead drug candidate for treating Thyroid Eye ...
Regulatory ApprovalsThe U.S. Food and Drug Administration (FDA) granted orphan drug designation to JR-446, a drug developed by MEDIPAL HOLDINGS CORPORATION and JCR Pharma...
Regulatory ApprovalsValneva announced that the FDA and CDC recommend pausing the use of their chikungunya vaccine, IXCHIQ®, in elderly individuals due to reported serious...
Regulatory ApprovalsTerumo Neuro announced the US commercial availability of the SOFIA™ 88 Neurovascular Support Catheter. This large-bore catheter is designed for relia...
Mergers and acquisitionsAdaptimmune Therapeutics plc announced the sale of its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for $55 million in cas...
Mergers and acquisitionsAleraCare, a provider of infusion and specialty pharmacy services, and PURE Healthcare, a medical group specializing in treating chronic conditions, a...
Mergers and acquisitionsAbbVie has completed its acquisition of Capstan Therapeutics, gaining access to CPTX2309, a first-in-class in vivo targeted lipid nanoparticle (tLNP) ...
Mergers and acquisitions23andMe, a genetics-led consumer healthcare company, has received court approval for the sale of substantially all of its assets to TTAM Research Inst...
Mergers and acquisitionsAbbVie announced the acquisition of Gilgamesh Pharmaceuticals' bretisilocin, a novel Phase 2 psychedelic compound for treating moderate-to-severe majo...
Mergers and acquisitionsBioNTech, a global immunotherapy company, announced its intent to acquire CureVac, a clinical-stage biotech company focused on mRNA-based therapies, i...
KnolScapePeople love to compare drug development to a marathon. It sounds noble, right? The long haul, the endurance, the solitary push.
clinical trial design softwareEvery transformative shift in clinical trial design begins with a question that challenges an assumption so embedded that it is rarely examined. For decades, that assumption has been this: every trial needs a live placebo group.
KnolAiAny Transformational change in the pharmaceutical research field often starts with the realisation that the industry’s evidentiary foundation is inherently fragmented.
systematic literature reviewThe pharma industry sits right at the intersection of breakthrough science and ironclad regulation. There’s practically zero room for error. AI promises to turbocharge drug discovery, speed up clinical trials, and simplify those exhausting regulatory submissions. But here’s the thing: there's a huge chasm between general-purpose AI and the truly reliable AI for life sciences needed for GxP environments.
AI for drug developmentThe pharmaceutical landscape in 2026 is defined by a paradox: we have more data than ever before, yet the path to a successful approved therapy remains fraught with costly delays.
AI Software for HealthcareFor the better part of a century, the assumption has been this: proprietary data is a competitive advantage, and competitive advantage is never shared.
Private by design. Speaks your language. Proven at scale
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
